Related Experiment Video
Updated: Jan 15, 2026
Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique
Published on: May 2, 2025
Adequate lymphadenectomy and adjuvant capecitabine warrant survival benefit in gallbladder cancer
M Di Martino1, B Ielpo2, S Cremona2
1Department of Health Sciences, University of Piemonte Orientale, Novara, Italy; Division of General Surgery, University Maggiore Hospital della Carità, 28100, Novara, Italy.
Background:
Significant heterogeneity exists in the management of resectable gallbladder cancer (GBC), regarding the extent of lymphadenectomy and the role of adjuvant chemotherapy (aCTx). This study investigates outcomes of resected GBC according to contemporary surgical oncology principles.
Methods:
The international database of the GBC Study Group was queried for patients with resected GBC between 2012 and 2022. Patients with ≥6 lymph nodes resected and aCTx were compared to those with inadequate lymphadenectomy or inadequate aCTX. Unadjusted and adjusted Cox regression models were employed to assess oncological outcomes.
Results:
Out of 656 patients, 300 patients (45.7 %) had ≥6 lymph nodes resected, 240 (36.5 %) received any aCTx 323 and 118 (17.9 %) received capecitabine aCTx. Patients with adequate lymphadenectomy exhibited prolonged disease-free survival (DFS) (HR 0.69, p = 0.004 CI 95 % 0.55-0.89) and overall survival (OS) (HR 0.68, p = 0.002 CI 95 % 0.54-0.87) in pN0 but not in pN + cases. Patients receiving adjuvant capecitabine demonstrated prolonged DFS (HR 1.48, p < 0.001 95 %CI 1.20-1.83) and OS followed a similar pattern (HR 1.67, p < 0.001, 95 %CI 1.34-2.09). In the multivariable analysis, underlying hepatic disease (HR 2.75, p = 0.001, 95 %CI 1.49-5.07), adequate lymphadenectomy (HR 0.67, p = 0.020, 95 %CI 0.48-0.94), T stage (HR 2.14, p < 0.001, 95 %CI 1.60-2.86), R status (HR 1.88, p = 0.008, 95 %CI 1.18-3.00), and capecitabine aCTx (HR 1.27, p = 0.039 95 %CI 1.01-1.61) were identified as predictors of OS. Despite presenting with more aggressive disease, patients with adequate lymphadenectomy and aCTx with capecitabine presented prolonged OS (15 vs 7.5 months, HR 0.53, p = 0.038, 95 %CI 0.29-0.96) compared to those without lymphadenectomy or aCTx.
Conclusions:
A significant proportion of patients still did not receive adequate lymphadenectomy and aCTx. Patients treated according to contemporary surgical oncology principles presented a survival benefit. These principles should be further evaluated considering the aggressiveness of GBC.
